IgG response against Staphylococcus aureus in patients with Netherton syndrome

• Conditions: Comel-Netherton Syndrome; Netherton Syndrome; 10014982

• Registration Number: NL-OMON53242
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

- Diagnosed with NS by an expert professional
- Aged 16 years or above
- Able to read patient information, fill out questionnaires and provide
informed consent

Exclusion Criteria

- Systemic antibiotics within the previous 4 weeks
- Topical antibiotics within the previous 7 days

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- IgG antibody levels against S. aureus antigens, and a panel of other<br /><br>bacterial antigens (e.g. Pseudomonas aeruginosa, Streptococcus pneumoniae)<br /><br>measured in serum of NS patients using a Luminex assay, and compared to IgG<br /><br>antibody levels in healthy S. aureus carriers and non-carriers, AD patients and<br /><br>EB patients.<br /><br>- A list of S. aureus proteins produced in the skin of NS patients. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Differences in IgG and IgG4 antibody levels in NS patients over time.<br />- Identification and characterization of S. aureus (skin and nose) in NS<br />patients.</p>